NTRA · earnings call history
Natera Q1 FY26 — Strong Revenue Growth and Record Oncology Volumes
Read the briefNatera Q4 FY25 — Record Revenue and MRD Growth, Strong 2026 Guidance
Read the briefNatera Q3 FY25 — Record Revenue and Signatera Growth Drive Raised Guidance
Read the briefNatera Q4 FY24 — Strong Revenue Growth and Cash Flow Generation with Robust Pipeline Progress
Read the briefBrowse all US companies on the earnings-call register.